Astrazeneca is not alone among big pharma groups to have come late to cell therapy, but the mists around its work here are slowly clearing. What could become Astra’s first clinical-stage Car-T therapy is AZD0754, and it targets the Steap2 antigen, a document seen by Evaluate Vantage reveals.